We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Rational indication for docetaxel rechallenge in metastatic castration-resistant prostate cancer.
- Authors
Heck, Matthias M; Thalgott, Mark; Retz, Margitta; Wolf, Petra; Maurer, Tobias; Nawroth, Roman; Hatzichristodoulou, Georgios; Gschwend, Jürgen E; Kübler, Hubert
- Abstract
Study Type - Therapy (case series) Level of Evidence 4 What's known on the subject? and What does the study add? Docetaxel rechallenge has shown preserved anti-tumour activity and has therefore been proposed as an option for further treatment in patients with metastatic castration-resistant prostate cancer, who have shown a good response to first-line chemotherapy with docetaxel. The present study provides evidence of docetaxel activity in patients who were treated with full-dose (75 mg/m(2) ) 3-weekly docetaxel at first-line chemotherapy and rechallenge. It shows that PSA response to first-line chemotherapy may provide a rational indication for docetaxel rechallenge.
- Publication
BJU international, 2012, Vol 110, Issue 11 Pt B, pE635
- ISSN
1464-410X
- Publication type
Journal Article
- DOI
10.1111/j.1464-410X.2012.11364.x